STOCK TITAN
  1. Home
  2. News
  3. ZVRA

Zevra Therapeutics, Inc. - ZVRA STOCK NEWS

Welcome to our dedicated page for Zevra Therapeutics news (Ticker: ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.

Zevra Therapeutics, Inc. (symbol: ZVRA) is a pioneering rare disease company dedicated to developing transformational therapies for conditions with limited or no treatment options. By combining science, data, and patient needs, Zevra aims to deliver life-changing solutions to individuals living with rare diseases. Their mission is to address these unmet medical needs through unique, data-driven development and commercialization strategies.

Zevra Therapeutics utilizes its proprietary Ligand Activated Therapy (LAT) approach to create improved prodrug versions of FDA-approved medications. These prodrugs target high-need areas such as pain management, ADHD, and other central nervous system diseases. Through this innovative technology, Zevra is overcoming complex drug development challenges and making new therapies accessible to the rare disease community.

Recent achievements include significant advancements in their pipeline projects, particularly in pain and ADHD treatment. The company is also known for its strategic partnerships, which enhance its research and development capabilities and accelerate the commercialization of its therapies. Financially, Zevra has a solid foundation, allowing it to focus on its core mission of addressing rare diseases and improving patients' lives.

For up-to-date information, news, and latest developments, Zevra encourages stakeholders to stay connected through their official contact points:

News

Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates

Rhea-AI Summary
Zevra Therapeutics, Inc. reports strong financial results for Q4 2023 with a net revenue of $13.2M and FY 2023 net revenue of $27.5M. The company made progress in launching OLPRUVA® and preparing for arimoclomol launch. Positive data from the KP1077 phase 2 study in idiopathic hypersomnia was highlighted. The company completed the acquisition of Acer Therapeutics, Inc., enhancing its rare disease assets and revenue potential. Financially, there was an increase in net revenue, but also an increase in R&D and G&A expenses, leading to a net loss for both Q4 and FY 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.03%
Tags
earnings
-
News

Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia

Rhea-AI Summary
Zevra Therapeutics, Inc. announces positive top-line data from its Phase 2 clinical trial evaluating KP1077 for idiopathic hypersomnia, showing clinically meaningful benefits for key symptoms. The study demonstrated improvements in excessive daytime sleepiness, sleep inertia, and brain fog, supporting the safety and tolerability of KP1077 for further development into a Phase 3 trial.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
clinical trial
-
News

Zevra Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) to participate in the 23rd Annual Needham Virtual Healthcare Conference. Presentation scheduled for April 8, 2024, at 3:45 p.m. ET. Management team available for one-on-one investor meetings. Webcast and archived presentation details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.42%
Tags
conferences
News

Zevra Therapeutics to Report 2023 Fourth Quarter and Full Year Financial Results on March 28, 2024

Rhea-AI Summary
Zevra Therapeutics, Inc. to host a conference call to discuss corporate and financial results for Q4 and full year 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
conferences earnings
-
News

Zevra Therapeutics Provides FDA Update on the PDUFA Action Date for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

Rhea-AI Summary
Zevra Therapeutics, Inc. announces FDA extension of arimoclomol NDA review for Niemann-Pick disease type C with a new PDUFA action date of September 21, 2024. The company remains optimistic about the potential of arimoclomol to help patients despite the delay.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.15%
Tags
none
-
News

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) announces Neil F. McFarlane, President and CEO, will present at investor conferences in March 2024. The company will participate in TD Cowen 44th Annual Health Care Conference and 36th Annual ROTH Conference. The live webcasts will be available on Zevra's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
conferences
News

Zevra Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) will present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The company's management team will also be available for one-on-one investor meetings. The live webcast will be accessible on the company's website, and the archived presentation will be available thereafter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.34%
Tags
conferences
-
News

Zevra Therapeutics Appoints Experienced Biopharma Executive Alvin Shih, MD, MBA, to the Board of Directors

Rhea-AI Summary
Zevra Therapeutics, Inc. appoints Alvin Shih, MD, MBA, to its Board of Directors. Dr. Shih brings extensive experience in biotechnology leadership and rare disease therapeutics development. He has held leadership roles at various biotechnology companies and has a strong background in drug development for rare diseases. Zevra's Board and management team express confidence in Dr. Shih's ability to contribute to the advancement of the company's therapeutic portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.5%
Tags
management
-
News

Zevra Therapeutics Receives FDA Acceptance of Resubmission of NDA for Arimoclomol as a Treatment for Niemann-Pick Disease Type C

Rhea-AI Summary
Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has announced that the U.S. FDA has assigned a PDUFA action date of June 21, 2024, for the resubmission of the New Drug Application (NDA) for arimoclomol as a first-in-class treatment for Niemann-Pick disease type C. The resubmission addresses concerns previously raised in the FDA's complete response letter and includes additional evidence supporting trial metrics and data from multiple additional studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.9%
Tags
clinical trial
News

Zevra Therapeutics Appoints Global Medical Leader, Adrian Quartel, M.D., FFPM, as Chief Medical Officer

Rhea-AI Summary
Zevra Therapeutics, Inc. (ZVRA) appoints Dr. Adrian Quartel, M.D., FFPM, as Chief Medical Officer, bringing extensive experience in the pharmaceutical industry. Dr. Quartel's appointment follows Zevra's recent acquisition of Acer Therapeutics, expanding their rare disease portfolio. The company aims to develop and commercialize therapies for rare and ultra-rare diseases with significant unmet needs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.21%
Tags
management

FAQ

What is the current stock price of Zevra Therapeutics (ZVRA)?

The current stock price of Zevra Therapeutics (ZVRA) is $8.49 as of December 20, 2024.

What is the market cap of Zevra Therapeutics (ZVRA)?

The market cap of Zevra Therapeutics (ZVRA) is approximately 458.1M.

What does Zevra Therapeutics, Inc. specialize in?

Zevra Therapeutics focuses on developing transformational therapies for rare diseases using their proprietary LAT technology.

What is the company's mission?

The mission of Zevra Therapeutics is to bring life-changing therapeutics to people living with rare diseases.

What is the Ligand Activated Therapy (LAT) approach?

The LAT approach is a proprietary method used by Zevra to create improved prodrug versions of FDA-approved medications.

Which areas of medical needs does Zevra's technology target?

Zevra's technology targets high-need areas such as pain management, ADHD, and other central nervous system diseases.

Who are the primary contacts for investor relations?

Primary contacts include Nichol Ochsner, David Schull, and Ignacio Guerrero-Ros, Ph.D.

How does Zevra ensure the financial stability of their projects?

Zevra has a solid financial foundation, allowing them to focus on their core mission of addressing rare diseases.

What recent achievements has Zevra made?

Zevra has made significant advancements in their pipeline projects, especially in pain and ADHD treatment.

What kind of partnerships does Zevra engage in?

Zevra engages in strategic partnerships to enhance research, development, and accelerate commercialization efforts.

How can stakeholders stay updated with Zevra's latest news?

Stakeholders can stay updated by connecting with official contact points including Nichol Ochsner and representatives from Russo Partners.

What is the significance of Zevra’s prodrug development?

Zevra's prodrug development is significant as it creates improved versions of existing FDA-approved drugs to better meet patient needs.

Stock ZVRA logo
Zevra Therapeutics, Inc.

Nasdaq:ZVRA

ZVRA Rankings

#3167 Ranked by Market Cap
N/A Ranked by Dividends

ZVRA Stock Data

458.05M
49.84M
6.62%
54.46%
7.7%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
CELEBRATION